Jan 12, 2022 / 02:00PM GMT
Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
Good morning, everyone. My name is Jess Fye. I'm a senior biotech analyst at JPMorgan, and we're continuing the 40th JPMorgan Healthcare Conference this morning with ImmunoGen. I'm joined by the company's CEO, Mark Enyedy, who's going to give a presentation on the business, and then we're going to go into some Q&A. (Operator Instructions)
So with that, let me pass it over to Mark.
Mark Joseph Enyedy - ImmunoGen, Inc. - President, CEO & Director
Good morning. Our thanks to Jess and the rest of the team at JPMorgan for the opportunity to speak with you today. Our presentation contains forward-looking statements. Please refer to our SEC filings for the risks and uncertainties that could cause our actual results to vary from those statements.
So for those of you who are new to ImmunoGen or revisiting the story, given our recent progress, we are developing the next generation of ADCs to improve outcomes for cancer patients by delivering targeted therapies with
ImmunoGen Inc at JPMorgan Healthcare Conference Transcript
Jan 12, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers